Hence IQWiG concluded for lurasidone in the severe treatment of schizophrenia and in the prevention of relapse: An extra benefit has not been proven. G-BA chooses on the level of added advantage This dossier evaluation is area of the early advantage assessment according to the Act on the Reform of the Market for Medicinal Items supervised by the G-BA. After publication of the dossier evaluation, the G-BA conducts a commenting treatment and makes a final decision on the degree of the added benefit.. Added benefit of lurasidone drug not proved for schizophrenia The drug lurasidone has been available since November 2014 for the treating adults with schizophrenia.The word obesity was constructed by the medical community, Kwan says. And the use of your body Mass Index, which measures obesity, as the primary factor to define weight problems, has led to the press overstating the rise of the condition greatly. This epidemic has been constructed to the benefit of the medical market that has in part medicalized the treatment of obesity over the years, Kwan says. While there could be a growth in ‘obesity,’ the BMI isn’t accurate always.